Výsledky vyhledávání - "Verena Hoeld"

Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic

Autor: Gregor Rossmueller, Irina Mirkina, Barbara Maurer, Verena Hoeld, Julia Mayer, Michael Thiele, Randolf J. Kerschbaumer, Alexander Schinagl

Publikováno v: Molecular Cancer Therapeutics. 22:555-569

High levels of macrophage migration inhibitory factor (MIF) in patients with cancer are associated with poor prognosis. Its redox-dependent conformational isoform, termed oxidized MIF (oxMIF), is a promising tumor target due to its selective occurren

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e2cee2d8cf1b5fc4604944e00e8efe1
https://doi.org/10.1158/1535-7163.mct-22-0676

Zobrazit plný text záznamu

Figure 2 from Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic

Autor: Alexander Schinagl, Randolf J. Kerschbaumer, Michael Thiele, Julia Mayer, Verena Hoeld, Barbara Maurer, Irina Mirkina, Gregor Rossmueller

Pharmacokinetics and BD of C0008, C0083, and C0090. A, BALB/c nude mice received a single intravenous injection of C0008, C0083, and C0090 mAbs (10 mg/kg), and plasma samples were collected 4, 10, 24, 48, and 96 hours thereafter. The plasma concentra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::209cee8e4651945929eaa3ce43d5adbf
https://doi.org/10.1158/1535-7163.22758809

Zobrazit plný text záznamu

Figure 1 from Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic

Autor: Alexander Schinagl, Randolf J. Kerschbaumer, Michael Thiele, Julia Mayer, Verena Hoeld, Barbara Maurer, Irina Mirkina, Gregor Rossmueller

Physicochemical characterization of the mAb variants revealed identical binding properties and reduced hydrophobicity of the bioengineered anti-oxMIF antibodies compared with C0008 (imalumab). A, Antibody specificity of oxMIF versus redMIF in solutio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47c8bc223a50a5bf55f0b3a95751c24b
https://doi.org/10.1158/1535-7163.22758812.v1

Zobrazit plný text záznamu

Figure 3 from Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic

Autor: Alexander Schinagl, Randolf J. Kerschbaumer, Michael Thiele, Julia Mayer, Verena Hoeld, Barbara Maurer, Irina Mirkina, Gregor Rossmueller

ON103 and ON203 mAbs with engineered Fc induce potent ADCC and ADCP. A, ON103 and ON203 trigger potent effector cell activation in ADCC reporter bioassays. Serial dilutions of mAbs were incubated for 6 hours with HCT116/pMIF target cells and Jurkat e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2169a0d0e556ed73571c2a632ec42f4e
https://doi.org/10.1158/1535-7163.22758806

Zobrazit plný text záznamu

Figure 6 from Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic

Autor: Alexander Schinagl, Randolf J. Kerschbaumer, Michael Thiele, Julia Mayer, Verena Hoeld, Barbara Maurer, Irina Mirkina, Gregor Rossmueller

ON203 inhibits tumor growth in a therapeutic prostate cancer xenograft model. A, Schematic presentation of the therapeutic prostate cancer xenograft model created with www.biorender.com. B, Tumor volume of subcutaneous PC3 tumor-bearing mice treated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d00c19033912e726f12301fb227e0835
https://doi.org/10.1158/1535-7163.22758797.v1

Zobrazit plný text záznamu

Figure 4 from Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic

Autor: Alexander Schinagl, Randolf J. Kerschbaumer, Michael Thiele, Julia Mayer, Verena Hoeld, Barbara Maurer, Irina Mirkina, Gregor Rossmueller

ON203 shows target-dependent cytokine release from PBMCs and reduced unspecific cytokine release compared with C0008 in an ADCR assay. ON203 and C0008 were incubated with human PBMCs for 24 hours in the presence (A–D) or in the absence (E–H) of H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76aa701044b64f32fa2504390039da1c
https://doi.org/10.1158/1535-7163.22758803.v1

Zobrazit plný text záznamu

Figure 5 from Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic

Autor: Alexander Schinagl, Randolf J. Kerschbaumer, Michael Thiele, Julia Mayer, Verena Hoeld, Barbara Maurer, Irina Mirkina, Gregor Rossmueller

ON203 is efficacious in a prophylactic prostate cancer xenograft model. A, Schematic presentation of the prophylactic prostate cancer xenograft model created with www.biorender.com. B, Tumor volume of subcutaneous PC3 tumor-bearing mice treated 15 ti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f4ba9aa9b89015f0cdadfe9dc2256a3
https://doi.org/10.1158/1535-7163.22758800.v1

Zobrazit plný text záznamu

Data from Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic

Autor: Alexander Schinagl, Randolf J. Kerschbaumer, Michael Thiele, Julia Mayer, Verena Hoeld, Barbara Maurer, Irina Mirkina, Gregor Rossmueller

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e805d80bf07cc910fba889bbd22b2940
https://doi.org/10.1158/1535-7163.c.6603184.v1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání